Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-011554
Filing Date
2025-08-14
Accepted
2025-08-14 16:05:22
Documents
51
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sngx-20250630x10q.htm   iXBRL 10-Q 1751537
2 EX-10.1 sngx-20250630xex10d1.htm EX-10.1 65851
3 EX-31.1 sngx-20250630xex31d1.htm EX-31.1 18345
4 EX-31.2 sngx-20250630xex31d2.htm EX-31.2 19679
5 EX-32.1 sngx-20250630xex32d1.htm EX-32.1 8189
6 EX-32.2 sngx-20250630xex32d2.htm EX-32.2 11067
  Complete submission text file 0001558370-25-011554.txt   7327576

Data Files

Seq Description Document Type Size
7 EX-101.SCH sngx-20250630.xsd EX-101.SCH 30806
8 EX-101.CAL sngx-20250630_cal.xml EX-101.CAL 37584
9 EX-101.DEF sngx-20250630_def.xml EX-101.DEF 150979
10 EX-101.LAB sngx-20250630_lab.xml EX-101.LAB 321453
11 EX-101.PRE sngx-20250630_pre.xml EX-101.PRE 243992
54 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20250630x10q_htm.xml XML 1574352
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14778 | Film No.: 251218777
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)